Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M
Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan.
Ann Rheum Dis. 2003 Jun;62(6):572-5. doi: 10.1136/ard.62.6.572.
To assess the effect of a combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism in hypertriglyceridaemic and/or hypertensive patients with gout.
Twenty seven patients with gout were included in a fenofibrate plus anti-hyperuricaemic agents combination study, and 25 in a losartan plus anti-hyperuricaemic agents combination study. Serum uric acid concentration, uric acid clearance, and 24 hour urinary uric acid excretion were measured before and two months after the addition of fenofibrate (300 mg once daily) or losartan (50 mg once daily) to anti-hyperuricaemic agents.
Combination therapy of fenofibrate or losartan with anti-hyperuricaemic agents, which included benzbromarone (50 mg once daily) or allopurinol (200 mg twice a day), significantly reduced serum uric acid concentrations in accordance with increased uric acid excretion.
A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest.
评估抗高尿酸血症药物联合非诺贝特和/或氯沙坦对高甘油三酯血症和/或高血压痛风患者尿酸代谢的影响。
27例痛风患者纳入非诺贝特加抗高尿酸血症药物联合研究，25例纳入氯沙坦加抗高尿酸血症药物联合研究。在抗高尿酸血症药物中添加非诺贝特（每日一次，300毫克）或氯沙坦（每日一次，50毫克）之前及之后两个月，测量血清尿酸浓度、尿酸清除率和24小时尿尿酸排泄量。
非诺贝特或氯沙坦与抗高尿酸血症药物（包括苯溴马隆（每日一次，50毫克）或别嘌醇（每日两次，200毫克））联合治疗，随着尿酸排泄增加，血清尿酸浓度显著降低。
非诺贝特或氯沙坦与抗高尿酸血症药物联合使用，是治疗高甘油三酯血症和/或高血压痛风患者的一个不错选择，尽管额外的降尿酸效果可能不大。
